Biomunex's ambition is to develop the next generation of immunotherapies in oncology: MAIT engagers, bispecific antibodies capable of identifying, mobilizing, and activating MAIT cells, a ...

Dr. Simon Plyte, Biomunex’s CSO, has been invited to present MAIT engagers preclinical data during an oral communication at 2025 SITC Annual meeting With a very attractive safety and efficacy profile, ...

“We took a break.” Antonella Elia surprised Caterina Balivo during today's episode of La Volta Buona, Friday, November 7, when asked what her partner Pietro Delle Piane gave her for her birthday.

Biomunex Pharmaceuticals, a French biopharmaceutical company specializing in the development of next generation immunotherapies based on the discovery and development of bispecific and multispecific ...